NCT07000110View on ClinicalTrials.gov

Anifrolumab Malignancy and Serious Infections Study

Not yet recruitingOBSERVATIONAL

Enrollment

3,506

Participants

Timeline

Start Date

November 28, 2025

Primary Completion Date

November 30, 2031

Study Completion Date

November 30, 2031

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

Anifrolumab

Anifrolumab prescribed per local practice

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Iqvia Pty Ltd

INDUSTRY

lead

AstraZeneca

INDUSTRY